Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Umbilical Cord Blood Endothelial Progenitor Cells (UCB-EPCs) are a cell-based therapeutic modality currently under preclinical investigation. These cells are typically characterized by the expression of the CD133 marker and are isolated from the mononuclear cell fraction of human umbilical cord blood. In research models of neonatal hypoxic-ischemic brain injury (HIBI), UCB-EPCs have demonstrated the ability to modulate neuroinflammatory responses, reduce brain tissue damage, preserve the integrity of the blood-brain barrier, and improve functional behavioral outcomes. While they represent a promising biologic approach for neuroprotection and vascular repair, they are currently utilized as experimental research tools rather than marketed pharmaceutical products.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on umbilical cord blood endothelial progenitor cells.